Technology to Treat Heart Failure: Friend or Foe?

Disclosures
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research

Related Links:

The Heart Rhythm Society said it is planning a virtual alternative to its annual sessions, while that option is under consideration for the European Society of Cardiology's specialty meeting.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Authors: Corrà U, Piepoli M, Giordano A Abstract Exercise oscillatory ventilation (EOV) is an ominous sign in heart failure due to reduced left ventricular ejection fraction (HFrEF) whatever it is represented. But EOV is detected also in normal healthy individuals and in other cardiovascular disease (CVD) patients, however, its prevalence in these is not completed clear. The aim was to describe the occurrence of EOV in healthy subjects and the overall population all CVD patients who performing symptom limited cardiopulmonary exercise testing (CPET). Healthy subjects were divided in athletes and normal subjec...
Source: Monaldi Archives for Chest Disease - Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research
CONCLUSION Relatively low use of technology may limit potential for health technology innovation for people of advanced age. Socioeconomic and ethnic disparities will amplify this. PMID: 32223848 [PubMed - in process]
Source: Journal of Primary Health Care - Category: Primary Care Tags: J Prim Health Care Source Type: research
Authors: Chalikias G, Kikas P, Thomaidis A, Rigopoulos P, Pistola A, Lantzouraki A, Zisimopoulos A, Tziakas D Abstract We assessed the effect of Sacubitril/Valsartan on circulating catecholamine levels in patients with HF in an observational cohort study. We included 108 consecutive HF patients attending our HF Outpatients Clinic who were eligible to Sacubitril/Valsartan according to the PARADIGM-HF inclusion and exclusion criteria. We furthermore included 58 stable HF patients under optimal medical therapy as a control group. Norepinephrine and epinephrine were measured with immunoradiometric assays at baseline, a...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
This case series found SARS-Cov-2 infection can cause pulmonary and systemic inflammation, leading to multi-organ dysfunction in high risk populations. In addition to respiratory distress/failure, acute cardiac injury and heart failure may also contribute to critical illness
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Authors: Maki H, Takeda N PMID: 32224600 [PubMed - in process]
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Condition:   Acute Heart Failure Intervention:   Sponsors:   Seoul National University Bundang Hospital;   Korean Society of Heart Failure Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ZOLL Medical, now a part of Asahi Kasei Group, won FDA approval for the latest version of its TherOx System. The product is designed to deliver SuperSaturated Oxygen (SSO2) therapy to limit heart muscle loss following “widowmaker” heart a...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Emergency Medicine Radiology Source Type: blogs
 No one in pharma needs to be told that COVID-19 is upending business as we know it. But in the face of this unprecedented change there is a great opportunity to adapt, improve and profit from new ways of working. And digital capabilities are the key to realising them, says Bertrand Bodson, Chief Digital Officer and Member of the Executive Board of Novartis in his keynote speech opening the eyeforpharma Virtual, a digital version of the Barcelona event, and available to delegates who can sign up for free athttps://virtual.eyeforpharma.com. Novartis is demonstrating how pharma can achieve rapid transformation...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
Conclusion: Here, we reveal several Nrf2 dose-responsive miRNA loci harboring putative upstream antioxidant response elements (AREs). Intriguingly, Nrf2-mediated miRNA responses were distinctly enriched for post-transcriptional regulation of cardiac-specific mRNAs. Altogether, these data reveal Nrf2 as a potent regulator of cardiac miRNA expression and provide novel candidates for future mechanistic investigation into the relationship between myocardial redox status and pathophysiology.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Mus musculus Source Type: research
More News: Cardiology | Cardiovascular | Heart | Heart Failure